Core Viewpoint - The 2024 Golden Bull Award for Dividend Return was awarded to Huate Dain, a company focused on the pharmaceutical industry, emphasizing its commitment to children's health and high-quality development [1][2]. Group 1: Event Overview - The 2025 High-Quality Development Forum for Listed Companies and the 27th Golden Bull Award Ceremony took place in Nantong, Jiangsu on October 29 [1]. - The theme of the forum was "Moving Forward with New Initiatives, Achieving Long-Term Goals through Practical Actions, and Innovating for the Future" [1]. Group 2: Award Details - The Golden Bull Award is a prestigious evaluation activity organized by China Securities Journal, established in 1999, focusing on transparency and professionalism [1]. - This year's awards included nine categories, such as "Most Investment Value Award," "Golden Bull Listed Company Dividend Return Award," and "Golden Bull Secretary Award" [2]. - The "Golden Bull Listed Company Dividend Return Award" was based on key indicators like total dividends, dividend yield, and frequency of dividends over recent years, resulting in the recognition of 60 listed companies [2].

华特达因（000915.SZ）10月28日在投资者互动平台表示，公司及子公司目前没有您提到的长效胰岛素 类似物产品的研发和合作。 （文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：子公司达因药业和"中国医学科学院药生所"战略合作协 议的主要方向和产品当中，有合作部分是长效胰岛素类似物产品，明年要进入临床？ ...

Core Insights - The company reported a significant increase in revenue and net profit for the third quarter of 2025, indicating strong financial performance [1] Financial Performance - The company achieved a revenue of 432,116,216.88 yuan in the third quarter of 2025, representing a year-on-year growth of 93.28% [1] - The net profit attributable to shareholders was 70,598,114.55 yuan, showing a year-on-year increase of 110.42% [1]

Core Insights - The company reported a revenue of 1.603 billion yuan for the first three quarters of 2025, representing a year-on-year growth of 16.30% [1] - The net profit attributable to shareholders reached 408 million yuan, with a year-on-year increase of 11.67% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 400 million yuan, showing a year-on-year growth of 15.80% [1]

Company Performance - Huate Dain reported Q3 performance with revenue of approximately 1.603 billion yuan, an increase of 16.3% year-on-year [1] - The net profit attributable to shareholders was about 408 million yuan, reflecting an increase of 11.67% year-on-year [1] - Basic earnings per share reached 1.7414 yuan, also up by 11.67% year-on-year [1] Market Context - As of the report, Huate Dain's market capitalization stands at 7.7 billion yuan [2] - The Chinese innovative drug sector has seen significant overseas licensing sales, totaling 80 billion US dollars this year [2]

Core Viewpoint - 华特达因 reported significant growth in both revenue and net profit for the third quarter of 2025, indicating strong operational performance and financial health [1] Financial Performance - The company's operating revenue reached 432 million yuan, representing a year-on-year increase of 93.28% [1] - The net profit attributable to shareholders was 70.6 million yuan, showing a year-on-year growth of 110.42% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 67.3 million yuan, reflecting a year-on-year increase of 153.51% [1]

Core Viewpoint - Huate Dain (000915) reported significant growth in both revenue and net profit for the third quarter of 2025, indicating strong operational performance and potential investment opportunities [1] Financial Performance - The company achieved a revenue of 432 million yuan in the third quarter, representing a year-on-year increase of 93.28% [1] - The net profit attributable to shareholders for the third quarter was 70.6 million yuan, showing a year-on-year growth of 110.42% [1] - For the first three quarters, the total revenue reached 1.603 billion yuan, with a year-on-year increase of 16.3% [1] - The net profit attributable to shareholders for the first three quarters was 408 million yuan, reflecting a year-on-year growth of 11.67% [1]

Financial Performance - For the first nine months of 2025, the company achieved operating revenue of CNY 1.603 billion, with a net profit attributable to shareholders of CNY 408 million, representing year-on-year growth of 16.30% and 11.67% respectively[4] - The pharmaceutical business generated operating revenue of CNY 1.578 billion and a net profit of CNY 757 million, reflecting increases of 16.77% and 9.64% compared to the same period in 2024[4] - In Q3 2025, the company reported operating revenue of CNY 432 million, a significant increase of 93.28% year-on-year, and a net profit of CNY 70.6 million, up 110.42% from the previous year[5] - The basic earnings per share for the first nine months of 2025 was CNY 1.7414, marking an increase of 11.67% compared to the same period last year[5] - Net profit for the period was ¥767,418,437.12, representing a 10.8% increase from ¥692,591,722.84 in the previous period[16] - Earnings per share (EPS) for the period was ¥1.7414, compared to ¥1.5594 in the prior period, reflecting a growth of 11.6%[16] Assets and Liabilities - The company's total assets as of September 30, 2025, were CNY 4.780 billion, a decrease of 3.06% from the end of the previous year[5] - The company's total current assets amount to ¥3,372,578,876.81, a decrease from ¥3,510,737,250.04 at the beginning of the period[12] - The total assets of the company are ¥4,779,984,839.06, down from ¥4,930,936,591.73[13] - The company's total liabilities amount to ¥473,747,067.84, an increase from ¥418,011,480.27[13] - Total liabilities increased to ¥573,205,007.48 from ¥518,499,753.28, indicating a rise of 10.6%[14] - The company's equity attributable to shareholders decreased by 2.08% to CNY 2.851 billion compared to the end of the previous year[5] - Total equity attributable to shareholders decreased to ¥2,851,053,959.18 from ¥2,911,651,440.88, a decline of 2.1%[14] Cash Flow - The net cash flow from operating activities for the first nine months was CNY 955 million, representing a 70.50% increase year-on-year[5] - The net cash flow from operating activities was CNY 954,987,097.75, an increase of 70.4% compared to CNY 560,093,957.28 in the previous period[18] - Total cash inflow from operating activities amounted to CNY 2,654,451,852.64, up from CNY 2,015,317,935.16, reflecting a growth of 31.6%[18] - Cash outflow from operating activities was CNY 1,699,464,754.89, compared to CNY 1,455,223,977.88, representing an increase of 16.8%[18] - The ending balance of cash and cash equivalents was CNY 1,820,357,317.28, an increase from CNY 1,610,259,774.32[18] Expenses - Sales expenses for the first nine months of 2025 amounted to CNY 342.8 million, a rise of 37.13% compared to the same period in 2024, attributed to higher marketing activity costs and sales personnel bonuses[9] - The company experienced a 2118.27% increase in credit impairment losses, amounting to CNY 6.6 million, mainly due to the recovery of large overdue accounts[9] - Research and development expenses were ¥68,738,075.33, slightly up from ¥64,281,936.19 in the prior period[15] - The company recorded a tax expense of ¥131,540,958.88, which is marginally higher than ¥129,753,178.59 in the previous period[16] Shareholder Information - Total number of common shareholders at the end of the reporting period is 27,598[10] - The largest shareholder, Shandong Huate Holding Group Co., Ltd., holds 22.00% of shares, totaling 51,544,340 shares[10] - The company has no preferred shareholders as indicated in the report[12] Other Financial Metrics - The company reported a significant increase in contract liabilities, which rose by 262.65% to CNY 203.7 million, primarily due to increased advance payments from customers[8] - The company reported a financial asset fair value change gain of ¥8,168,115.06, compared to ¥6,090,195.26 in the previous period[16] - Cash inflow from investment activities totaled CNY 2,012,895,539.01, down from CNY 2,186,690,952.50, indicating a decrease of 7.9%[18] - Cash outflow from investment activities increased to CNY 2,234,199,712.60 from CNY 2,081,136,231.58, marking a rise of 7.4%[18] - Cash flow from financing activities resulted in a net outflow of CNY -973,075,444.00, compared to CNY -1,090,241,186.50 previously[18]

Core Insights - The company reported a third-quarter revenue of 432 million, representing a year-over-year increase of 93.28% [1] - The net profit for the third quarter was 70.6 million, showing a year-over-year growth of 110.42% [1] - For the first three quarters, the total revenue reached 1.603 billion, with a year-over-year increase of 16.30% [1] - The net profit for the first three quarters was 408 million, reflecting a year-over-year growth of 11.67% [1]

山东华特达因健康股份有限公司 董事会薪酬与考核委员会工作规则 第一章 总则 第一条 为进一步建立健全公司董事(非独立董事)及高级管理人员的考核和 薪酬管理制度，完善公司治理结构，根据《中华人民共和国公司法》《上市公司 治理准则》《上市公司独立董事管理办法》《公司章程》等规定，制定本工作规 则。 第二条 薪酬与考核委员会是董事会按照股东会决议设立的专门工作机构， 主要负责制定公司董事及高级管理人员的考核标准并进行考核，负责制定、审查 公司董事及高级管理人员的薪酬政策与方案，对董事会负责。 第三条 本规则所称董事是指在本公司领取薪酬的董事长、董事，高级管理 人员是指董事会聘任的总经理、财务总监、副总经理、董事会秘书及由总经理 提请董事会聘任的其他高级管理人员。 第二章 人员组成 第四条 薪酬与考核委员会由三名董事组成，其中独立董事二名。 第五条 薪酬与考核委员会委员由董事长、过半数独立董事或者全体董事的 三分之一提名，并由董事会选举产生。 第六条 薪酬与考核委员会设主任委员一名，由独立董事担任，主任委员由 董事长提名，经董事会选举产生。 第七条 薪酬与考核委员会任期与董事会任期一致，委员任期届满，连选可 以连任。 ...